Summary:
The number of CD34+ cells infused influences the speed of hematologic recovery post-transplant. There are limited data on whether ideal (IBW) or actual (ABW) body weight should be used to calculate CD34+ cell dose. We compared the correlation between recovery to 0.5 × 109/l neutrophils and the CD34+ cell dose based upon ABW as well as IBW in 87 patients autografted for cancer. ABW was ⩾25% over IBW in 43% of patients. The median number of CD34+ cells administered was 3.6 × 106/kg ABW and 4.2 × 106/kg IBW. The time to neutrophil recovery was 8–15 days (median 10). There was a stronger inverse correlation between CD34+ cell dose/IBW and neutrophil recovery (r2=0.308; P<0.0001) than between CD34+ cell dose/ABW and neutrophil recovery (r2=0.267; P<0.0001). The median time to neutrophil recovery was comparable for those receiving ⩾2 × 106/kg CD34+ cells/kg IBW as well as ABW (10 days) and those receiving ⩾2 × 106/kg CD34+ cells/kg IBW but <2/kg ABW (10 days), but was significantly slower for those receiving <2 × 106/kg CD34+ cells/kg IBW (12 days). These data show that the CD34+ cell dose based on IBW is a better predictor of neutrophil recovery after autotransplantation.
Similar content being viewed by others
References
Mehta J, Powles R, Horton C et al. Factors affecting engraftment and hematopoietic recovery after unpurged autografting in acute leukemia. Bone Marrow Transplant 1996; 18: 319–324.
Bensinger WI, Longin K, Appelbaum F et al. Peripheral blood stem cells (PBSCs) collected after recombinant granulocyte colony stimulating factor (rhG-CSF): an analysis of factors correlating with the tempo of engraftment after transplantation. Br J Haematol 1994; 87: 825–831.
Weaver CH, Hazelton B, Birch R et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 1995; 86: 3961–3969.
Ketterer N, Salles G, Raba M et al. High CD34(+) cell counts decrease hematologic toxicity of autologous peripheral blood progenitor cell transplantation. Blood 1998; 91: 3148–3155.
Shpall EJ, Champlin R, Glaspy JA . Effect of CD34+ peripheral blood progenitor cell dose on hematopoietic recovery. Biol Blood Marrow Transplant 1998; 4: 84–92.
Waples JM, Moreb JS, Sugrue M et al. Comparison of autologous peripheral blood stem cell dosing by ideal vs actual body weight. Bone Marrow Transplant 1999; 23: 867–873.
Mehta J, Powles R, Treleaven J et al. Long-term follow-up of patients undergoing allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission after cyclophosphamide-total body irradiation and cyclosporine. Bone Marrow Transplant 1996; 18: 741–746.
Mehta J, Powles R, Treleaven J et al. Number of nucleated cells infused during allogeneic and autologous bone marrow transplantation: an important modifiable factor influencing outcome. Blood 1997; 90: 3808–3810.
Singhal S, Powles R, Kulkarni S et al. Comparison of marrow and blood cell yields from the same donors in a double-blind, randomized study of allogeneic marrow vs blood stem cell transplantation. Bone Marrow Transplant 2000; 25: 501–505.
Mehta J, Oyama Y, Winter J et al. CD34+ cell collection efficiency does not correlate with the pre-leukapheresis hematocrit. Bone Marrow Transplant 2001; 28: 597–601.
Mehta J, Singhal S, Gordon L et al. Cobe Spectra is superior to Fenwal CS 3000 Plus for collection of hematopoietic stem cells. Bone Marrow Transplant 2002; 29: 563–567.
Sutherland DR, Anderson L, Keeney M et al. The ISHAGE guidelines for CD34+ cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering. J Hematother 1996; 5: 213–226.
Devine DJ . Gentamicin therapy. Drug Intell Clin Pharm 1974; 8: 650–655.
Acknowledgements
This work was supported in part by the Auxiliary Board of the Northwestern Memorial Hospital.
Author information
Authors and Affiliations
Additional information
The first two authors contributed equally to this work.
Rights and permissions
About this article
Cite this article
Ali, M., Oyama, Y., Monreal, J. et al. Ideal or actual body weight to calculate CD34+ cell doses for autologous hematopoietic stem cell transplantation?. Bone Marrow Transplant 31, 861–864 (2003). https://doi.org/10.1038/sj.bmt.1703955
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1703955
- Springer Nature Limited
Keywords
This article is cited by
-
Impact of body mass index (BMI) on the efficacy of plerixafor for hematopoietic progenitor cell (HPC) mobilization
Bone Marrow Transplantation (2022)
-
The use of adjusted ideal body weight for overweight patients undergoing HPC mobilisation for autologous transplantation
Annals of Hematology (2012)
-
Actual or ideal body weight to calculate CD34+ cell dose in patients undergoing autologous hematopoietic SCT for myeloma?
Bone Marrow Transplantation (2009)
-
Significance of low peripheral blood CD34+ cell numbers prior to leukapheresis: what should the threshold required for apheresis be?
Bone Marrow Transplantation (2008)
-
Difficult stem cell mobilization despite adequate CD34+ cell dose predicts shortened progression free and overall survival after autologous HSCT for lymphoma
Bone Marrow Transplantation (2007)